Stockysis — AI-Powered Stock News & Sentiment Analysis

Roth Capital Maintains Buy on OptimizeRx, Lowers Price Target to $18

Benzinga Newsdesk www.benzinga.com Negative 62.3%

Neg 62.3% Neu 0% Pos 0%

Roth Capital analyst Richard Baldry maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $32 to $18.

Comments

No comments yet. Be the first!